Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
NCT04992156 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2022-05-19
Summary
To investigate parameters based on 18F-FES-PET/CT so as to estimate the outcome of palbociclib combined with endocrine therapy in patients with HR+/HER2-MBC.
Conditions
Interventions
- DRUG
-
Palbociclib 125mg/d
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Biyun Wang, Dr · Fudan University
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-03-15
- Primary Completion
- 2022-03-15
- Completion
- 2022-04-15
Countries
- China
Study Locations
More Related Trials
-
PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer
NCT01712815 ·Status: TERMINATED ·Phase: NA
-
Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer
NCT05486182 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer
NCT03442504 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
NCT06909604 ·Status: RECRUITING ·Phase: NA
-
Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer
NCT03507088 ·Status: COMPLETED ·Phase: NA
-
Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer
NCT01627704 ·Status: COMPLETED ·Phase: NA
-
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
NCT06557148 ·Status: RECRUITING
-
Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES
NCT03873428 ·Status: RECRUITING ·Phase: NA
-
PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer
NCT00236275 ·Status: COMPLETED ·Phase: PHASE3
-
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
NCT04252859 ·Status: TERMINATED ·Phase: PHASE2
-
Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer
NCT01814449 ·Status: UNKNOWN
-
18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
NCT02938546 ·Status: UNKNOWN ·Phase: PHASE3
-
[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers
NCT04320030 ·Status: COMPLETED ·Phase: PHASE2
-
Positron Emission Tomography in Patients With Breast Cancer
NCT00001385 ·Status: COMPLETED
-
Characterizing Breast Cancer With 18F-FES PET/CT
NCT05613270 ·Status: UNKNOWN ·Phase: NA
-
Axillary Surgery De-escalation After Neoadjuvant Therapy Using Dedicate Breast PET
NCT05914402 ·Status: RECRUITING ·Phase: NA
-
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma
NCT05960201 ·Status: COMPLETED ·Phase: PHASE2
-
Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer
NCT04411966 ·Status: COMPLETED ·Phase: NA
-
Palbociclib and FES PET
NCT02806050 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of 18F-FAPI-RGD in Breast Tumors
NCT05976620 ·Status: COMPLETED
-
Breast PET Feasibility
NCT03198442 ·Status: COMPLETED ·Phase: NA
-
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
NCT02149173 ·Status: TERMINATED ·Phase: NA
-
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
NCT02409316 ·Status: COMPLETED ·Phase: PHASE2
-
Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor
NCT06344767 ·Status: COMPLETED
-
Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer
NCT00572728 ·Status: COMPLETED ·Phase: PHASE2